TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 1349301
Drug: 0.4 mg
Normalized name: biotin 0.4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4 mg LHRH nasal spray three times daily for 4 weeks
Study: 1349301
Drug: 0.4 mg
Normalized name: biotin 0.4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4 mg LHRH nasal spray
Study: 8535553
Drug: Indomethacin 25
Normalized name: indomethacin 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin 25 mg three times daily
Study: 30193810
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (Conventional therapy for upper extremity for 60 minutes, 5 times per week for 4 weeks)
Study: 3387508
Drug: Hypnotic suggestion
Normalized name: Synotic
DrugBank: Fluocinolone acetonide (DB00591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hypnotic suggestion (Experiment 2)
Study: 3387508
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (Experiment 2)
Study: 29049039
Drug: Blood samples
Normalized name: dragon's blood extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blood samples collected immediately after interrupting the medication from peripheral vein and CVC lines.
Study: 29049039
Drug: Blood samples
Normalized name: dragon's blood extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blood samples collected 5 minutes after interrupting the infusion from peripheral vein and CVC lines.
Study: 29049039
Drug: CVC line
Normalized name: Gallus gallus gizzard lining preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: CVC line used for infusion.
Study: 23958147
Drug: Reduced high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reduced high-dose volume radiation therapy (RHDVRT)
Study: 23958147
Drug: Standard whole-bladder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard whole-bladder radiation therapy (sRT)
Study: 20542736
Drug: Methylprednisolone (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylprednisolone (500 mg/day orally for 3 consecutive days per month for 3-4 years)
Study: 20542736
Drug: Placebo (identical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (identical tablets to methylprednisolone)
Study: 17705052
Drug: Thrombolytic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrombolytic therapy (urokinase 12 h, urokinase 2 h, rtPA 50 mg, rtPA 100 mg) in group I
Study: 17705052
Drug: Anticoagulants (heparin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anticoagulants (heparin, nadroparin) in group II
Study: 20586860
Drug: Cimetidine (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine (800 mg/day)
Study: 12749247
Drug: Famotidine (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Famotidine (40 mg/day) or Nizatidine (300 mg/day)
Study: 12749247
Drug: No histamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: No histamine 2 receptor antagonists
Study: 16335001
Drug: Canada split
Approvals — FDA: no, EMA: no, PMDA: no
Description: Canada split influenza virus vaccine (trial group)
Study: 2282421
Drug: intermittent treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: intermittent treatment (placebo)
Study: 2282421
Drug: continuous treatment
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: continuous treatment (control)
Study: 7382709
Drug: Preoperative radiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative radiation therapy and surgery
Study: 7382709
Drug: Surgery and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgery and postoperative radiation therapy
Study: 7382709
Drug: Surgery and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgery and postoperative radiation therapy plus radical radiation therapy (for oral cavity and oropharynx lesions)
Study: 26775385
Drug: Sedoanalgesia (Group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sedoanalgesia (Group S): 1 mg/kg ketamine and 1 mg/kg propofol for induction, followed by infusion of 100-150 μg kg(‐1) min(‐1) propofol and 0.25 mg kg(‐1) h(‐1) ketamine for maintenance
Study: 26775385
Drug: General anesthesia
Normalized name: Ethers for general anesthesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: General anesthesia (Group G): 8% sevoflurane by inhalation with 50% nitrous oxide in oxygen for induction, maintained with sevoflurane (2%) and 50% nitrous oxide in oxygen
Study: 7919750
Drug: Formula supplements
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formula supplements
Study: 28142160
Drug: Tiopronin 500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiopronin 500 mg
Study: 17234566
Drug: Craniosacral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Craniosacral therapy
Study: 17234566
Drug: Acupuncture and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture and craniosacral therapy
Study: 17234566
Drug: All treatments
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All treatments from one practitioner
Study: 15199091
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy (MVAC: methotrexate, vinblastine, doxorubicin, and cisplatin)
Study: 11978332
Drug: Amodiaquine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amodiaquine (10 mg/kg per day for 3 days) plus artesunate (4 mg/kg per day for 3 days)
Study: 11978332
Drug: Amodiaquine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amodiaquine (10 mg/kg per day for 3 days) and placebo
Study: 10176148
Drug: diacerein 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: diacerein 100 mg/day plus standard osteoarthritic therapy for 6 months, followed by a 3-month monitoring period without diacerein
Study: 10176148
Drug: standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: standard therapy alone for the entire 9-month period
Study: 10176148
Drug: diacerein plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: diacerein plus standard therapy
Study: 10176148
Drug: standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: standard therapy alone
Study: 10176148
Drug: standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: standard therapy group
Study: 1688616
Drug: Hydrazine sulfate
Normalized name: Hydrazine Sulfate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrazine sulfate (60 mg, three times daily)
Study: 31484539
Drug: Treatment arm
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment arm 1 (not specified in detail)
Study: 31484539
Drug: Treatment arm
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment arm 2 (not specified in detail)
Study: 31484539
Drug: Treatment arm
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment arm 3 (initial treatment with etanercept and methotrexate)
Study: 31484539
Drug: Treatment to
Normalized name: Lice Treatment Topical lotion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment to target aimed at inactive disease (all arms)
Study: 23749293
Drug: BG-12 (dimethyl
Approvals — FDA: no, EMA: no, PMDA: no
Description: BG-12 (dimethyl fumarate) 240 mg twice daily (BID)
Study: 23797999
Drug: BG-12 (dimethyl
Approvals — FDA: no, EMA: no, PMDA: no
Description: BG-12 (dimethyl fumarate) 240 mg three times daily (TID)
Study: 16917670
Drug: A‐V Impulse
Approvals — FDA: no, EMA: no, PMDA: no
Description: A‐V Impulse System applied for 2 hours daily for 5 postoperative days
Study: 11422030
Drug: PTU 100
Normalized name: PTU 100 MG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: PTU 100 mg three times daily
Study: 11422030
Drug: PTU plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: PTU plus thyroxine 25 microg once daily
Study: 9101342
Drug: Buspirone (7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buspirone (7.5 mg)
Study: 20657533
Drug: Topical silver
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical silver oxide ointment
Study: 18981465
Drug: Cilengitide 500
Normalized name: Cilengitide
DrugBank: Cilengitide (DB11890)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cilengitide 500 mg
Study: 18981465
Drug: Cilengitide 2000
Normalized name: Cilengitide
DrugBank: Cilengitide (DB11890)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cilengitide 2000 mg
Study: 15467103
Drug: Cystoseira canariensis
Normalized name: Cystoseira tamariscifolia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cystoseira canariensis supplementation (1200 mg/d)
Study: 7987780
Drug: Group behavioral-cognitive
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group behavioral-cognitive therapy
Study: 7987780
Drug: Group behavioral-cognitive
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group behavioral-cognitive therapy with imipramine
Study: 2602607
Drug: Verapamil plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil plus Isosorbide Dinitrate (120 mg verapamil + 20 mg isosorbide dinitrate)
Study: 9514436
Drug: Verapamil (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil (120 mg)
Study: 793956
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment with prednisone
Study: 793956
Drug: Higher doses
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher doses of prednisone
Study: 31143396
Drug: Gel fortified
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gel fortified with 0.5% chlorhexidine and 70% ethyl alcohol (in a volume ratio of 20:2:1)
Study: 31143396
Drug: Plain non-sterile
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Plain non-sterile gel
Study: 25017624
Drug: Normal standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal standard treatment
Study: 16580907
Drug: Cetirizine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cetirizine (20 mg/d)
Study: 16580907
Drug: Pilsicainide (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pilsicainide (150 mg/d)
Study: 15288212
Drug: 30 microg
Normalized name: Levonorgestrel 30 microgram oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 microg ethinylestradiol + 2 mg dienogest (30EE/DNG)
Study: 15288212
Drug: 20 microg
Normalized name: Calcifediol 20 microgram oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 microg ethinylestradiol + 2 mg dienogest (20EE/DNG)
Study: 15288212
Drug: 10 microg
Normalized name: Estradiol 10 microgram vaginal tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 microg ethinylestradiol + 2 mg estradiol valerate + 2 mg dienogest (EE/EV/DNG)
Study: 8221821
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg of extended-release isradipine for 30 days
Study: 3767522
Drug: AVP-antagonist, d(CH2)5Tyr(Me)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AVP-antagonist, d(CH2)5Tyr(Me) AVP, 5 micrograms/kg i.v.
Study: 24626140
Drug: Contrast training
Normalized name: Contrased
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contrast training (CT) program (isometric + plyometric), no external loads, twice a week for 12 weeks
Study: 23647956
Drug: Telaprevir monotherapy
Normalized name: Telaprevir
DrugBank: Telaprevir (DB05521)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Telaprevir monotherapy
Study: 23647956
Drug: Telaprevir plus
Normalized name: Telaprevir
DrugBank: Telaprevir (DB05521)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Telaprevir plus peginterferon alfa-2a and ribavirin (triple therapy)
Study: 20133188
Drug: Cognitive-behavioral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral therapy for insomnia (CBT‐I)
Study: 16283367
Drug: HRT+ (hormone
Approvals — FDA: no, EMA: no, PMDA: no
Description: HRT+ (hormone replacement therapy)
Study: 12557135
Drug: Low-dose growth
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose growth hormone (0.05 mg. kg(‐1). day(‐1))
Study: 10376126
Drug: Naltrexone (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naltrexone (50 mg p.o. daily)
Study: 8745894
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of 5% w/w benzoyl peroxide and 3% w/w erythromycin
Study: 1535215
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of erythromycin and benzoyl peroxide
Study: 1796233
Drug: 800 mg
Normalized name: bran 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 mg daily x 3
Study: 1796233
Drug: 1200 mg
Normalized name: aspirin 1200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1200 mg daily x 3
Study: 1796233
Drug: 800 mg
Normalized name: bran 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 mg daily x 7
Study: 30114252
Drug: Surveillance cues
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surveillance cues (e.g., photographs of watching eyes)
Study: 27561827
Drug: Metformin treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin treatment for 8 weeks (TG)
Study: 28222641
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (SG)
Study: 20826250
Drug: beta-blocker utilization
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: beta-blocker utilization at discharge
Study: 20826250
Drug: beta-blocker dosing
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: beta-blocker dosing categories at discharge
Study: 20826250
Drug: beta-blocker dose
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: beta-blocker dose change between discharge and 3 weeks
Study: 20826250
Drug: Predictors of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Predictors of very low beta-blocker doses
Study: 18456521
Drug: Non-opioid analgesics
Normalized name: Non-opioid analgesics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-opioid analgesics (NOAs), median intake of 1325 mg/week ibuprofen-equivalents (IE) for 46 subjects using NOAs
Study: 18456521
Drug: Non-opioid analgesics
Normalized name: Non-opioid analgesics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-opioid analgesics (NOAs)
Study: 15584985
Drug: Low-dose PLT
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose PLT transfusions (3 PLT units)
Study: 15584985
Drug: Standard-dose PLT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose PLT transfusions (5 PLT units)
Study: 10859038
Drug: Unfractionated heparin
Normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unfractionated heparin or low-molecular-weight heparin (LMWH)
Study: 10859038
Drug: Long-term low-molecular-weight
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-term low-molecular-weight heparin (LMWH)
Study: 3707800
Drug: nalbuphine 4.5,
Approvals — FDA: no, EMA: no, PMDA: no
Description: nalbuphine 4.5, 8, 15, 25 or 50 mg/70 kg
Study: 3707800
Drug: morphine 3,
Approvals — FDA: no, EMA: no, PMDA: no
Description: morphine 3, 5, 10 or 17.5 mg/70 kg
Study: 3707800
Drug: nalbuphine (highest
Approvals — FDA: no, EMA: no, PMDA: no
Description: nalbuphine (highest dose)
Study: 26169094
Drug: High-dose esomeprazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose esomeprazole (80 mg IV, then 8 mg/h continuous infusion for 3 days)
Study: 26169094
Drug: Conventional dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional dose esomeprazole (40 mg IV every 12 h for 72 h)
Study: 17215611
Drug: Pelvic muscle
Normalized name: urinary incont device, pelvic muscle toner, elect
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pelvic muscle enforcement program by biofeedback and electrical stimulation for 30 minutes per session, twice a week for 6 weeks, followed by self-exercise of pelvic floor muscle (50-60 repetitions per session, 3 times a day for 6 weeks)
Study: 9223884
Drug: Epidural buprenorphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural buprenorphine 0.1 mg (bolus injection)
Study: 9223884
Drug: Epidural buprenorphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural buprenorphine 0.3 mg (continuous infusion)
Study: 9223884
Drug: Epidural droperidol
Normalized name: Droperidol
DrugBank: Droperidol (DB00450)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epidural droperidol 2.5 mg (bolus injection)
Study: 9223884
Drug: Epidural droperidol
Normalized name: Droperidol
DrugBank: Droperidol (DB00450)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epidural droperidol 5 mg (continuous infusion)
Study: 8163613
Drug: Cefamandole (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefamandole (single injection at operative site during local anesthesia)
Study: 3019976
Drug: High-dose cisplatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose cisplatin (120 mg/m2 every 4 weeks)
Study: 3019976
Drug: Low-dose cisplatin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose cisplatin (80 mg/m2 every 3 weeks)
Study: 7512356
Drug: VM-26 dose
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: VM-26 dose levels (60, 80, 100, 120 mg/m2/day)
Study: 7512356
Drug: VM-26 dose
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: VM-26 dose level of 120 mg/m2/day
Study: 2893038
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg of single-strand recombinant tissue plasminogen activator (rTPA) in 3 hours (n = 73)
Study: 2893038
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg of single-strand recombinant tissue plasminogen activator (rTPA)
Study: 29504252
Drug: AZL-M/CLD 20/12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZL-M/CLD 20/12.5 mg
Study: 29504252
Drug: OLM/HCTZ 20/12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: OLM/HCTZ 20/12.5 mg
Study: 25699397
Drug: 3DCRT (three-dimensional
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3DCRT (three-dimensional conformal radiation therapy)
Study: 20609025
Drug: Resilon filled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resilon filled with immediate post space preparation leaving 5 mm of apical filling
Study: 20609025
Drug: Resilon filled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resilon filled with delayed post space preparation for 1 week leaving 5 mm of material apically
Study: 20609025
Drug: Resilon filled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resilon filled with immediate post space preparation leaving 3 mm of material apically
Study: 20609025
Drug: Resilon filled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resilon filled with delayed post space preparation for 1 week leaving 3 mm of material apically
Study: 16046102
Drug: 1600 mg
Normalized name: glycerin 1600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1600 mg SAMe (pharmaceutical dose)
Study: 16046102
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg SAMe (nutraceutical dose)
Study: 12122721
Drug: Somatostatin 14
Approvals — FDA: no, EMA: no, PMDA: no
Description: Somatostatin 14 (S-14) infusion at a dose of 6 mg/24 h (days 1-6) and 3 mg/24 h (day 7)
Study: 1498074
Drug: Sequential MTX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential MTX (300 mg/m2) and FU (900 mg/m2) with leucovorin rescue
Study: 1498074
Drug: FU alone
Normalized name: fu ling
Approvals — FDA: no, EMA: no, PMDA: no
Description: FU alone (450 mg/m2/d for five days)
Study: 1498074
Drug: Sequential MTX/FU
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential MTX/FU
Study: 1498074
Drug: Sequential MTX/FU
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential MTX/FU and FU alone
Study: 17198906
Drug: Aliskiren monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aliskiren monotherapy
Study: 17198906
Drug: Aliskiren and
Normalized name: aliskiren and amlodipine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aliskiren and valsartan in combination
Study: 17198906
Drug: Valsartan/hydrochlorothiazide (160/12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valsartan/hydrochlorothiazide (160/12.5 mg)
Study: 15389347
Drug: Losartan (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan (50 to 100 mg once daily)
Study: 31154239
Drug: Conventional group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional group therapy plus an additional 10 hours of group therapy focusing on stimulant use
Study: 31154239
Drug: Conventional group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional group therapy only (treatment as usual)
Study: 28334419
Drug: Breast-conserving therapy
Normalized name: chicken breast preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Breast-conserving therapy (BCT) with good/excellent cosmetic outcomes
Study: 28334419
Drug: Breast-conserving therapy
Normalized name: chicken breast preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Breast-conserving therapy (BCT) with fair/poor cosmetic outcomes
Study: 21464685
Drug: Intervention group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention group (12 weekly healthy lifestyle sessions based on the Diabetes Prevention Program curriculum)
Study: 11764128
Drug: 5% NaOCl
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% NaOCl treatment after phosphoric acid treatment
Study: 8329783
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg with 6‐minute lockout (n = 10)
Study: 8329783
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg with 12‐minute lockout (n = 12)
Study: 8329783
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg with 20‐minute lockout (n = 12)
Study: 31578100
Drug: OnabotulinumtoxinA administered
Normalized name: Onabotulinumtoxina
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: OnabotulinumtoxinA administered by a specialist nurse
Study: 31578100
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of onabotulinumtoxinA scenarios
Study: 31176028
Drug: Scheduled-dose multimodal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scheduled-dose multimodal analgesia with minimal opiate supply (group A)
Study: 31176028
Drug: Scheduled-dose multimodal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scheduled-dose multimodal analgesia with traditional opiate supply (group B)